XB002: Model-Based Dose Selection for a Novel Anti-Tissue Factor ADC With a ZLA Payload for the Treatment of Solid Tumours
Time: 11:45 am
day: Track B - Day 1 - AM
Details:
- Review how efficacy data from Pharmacology tumour models in mice and PK data from monkeys were used to predict XB002 human PK and estimate human efficacious dose
- Understand how nonclinical safety in cynomolgus monkeys demonstrated adequate safety margins for the range of doses explored in the FTIH study
- Assess how the PK model was fitted to the human PK from the FTIH dose escalation phase to refine dose predictions
